MedTrace Logo

Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain

NCT05196386 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-11

No results posted yet for this study

Summary

Many treatments with WHO grade III opioids are being introduced in the rheumatology department for non-cancerous pain. The duration of this treatment prescribed at discharge is often uncontrolled and sometimes leads to significant addiction.

The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department.

The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.

Conditions

  • Non-cancerous Pain
  • Opioid Use

Interventions

BEHAVIORAL

Admission conciliation interview

Previous treatment conciliation at hospital admission

BEHAVIORAL

Discharge conciliation interview

Allocated treatment during hospital stay

BEHAVIORAL

Targeted pharmaceutical interview

Specific information about treatment delivered by pharmacist

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Principal Investigators

  • Olivier VITTECOQ, Pr · University Hospital, Rouen

  • Remi VARIN, Pr · University Hospital, Rouen

  • Catherine CHENAILLER, Dr · University Hospital, Rouen

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-06
Primary Completion
2023-08-28
Completion
2023-08-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05196386 on ClinicalTrials.gov